Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Alters But Doesn’t Change M&A Machine In 2020

$12bn Viatris Merger Completes In Remarkable Year

Executive Summary

Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.

You may also be interested in...



AmerisourceBergen Strikes $6.5bn Deal For Alliance

AmerisourceBergen has struck a $6.5bn deal to acquire the majority of the Alliance Healthcare businesseses from Walgreens Boots Alliance, giving it access to Alliance’s generics assets in Europe.

Siegfried Achieves Desired Scale After Completing Novartis Plant Deal

Siegfried has completed the acquisition of two Spanish manufacturing facilities from Novartis, in a move that will significantly enhance the Swiss CDMO’s capacity.

Alexion To Join With AZ Ahead Of US Soliris Biosimilars In 2025

Amgen will be able to launch its US Soliris biosimilar around two years ahead of patent expiry under a settlement agreement. The brand’s manufacturer, Alexion, discussed the threat as AstraZeneca pounced with a $39bn takeover agreement.

Related Content

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel